Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 34
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Tahara, Atsuo and Takasu, Toshiyuki 2018. Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 391, Issue. 4, p. 395.
    Wzgarda, Anna Kleszcz, Robert Prokop, Monika Regulska, Katarzyna Regulski, Milosz Paluszczak, Jaroslaw and Stanisz, Beata J. 2017. Unknown face of known drugs – what else can we expect from angiotensin converting enzyme inhibitors?. European Journal of Pharmacology, Vol. 797, Issue. , p. 9.
    Patel, Seema 2017. Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: A comprehensive review. The Journal of Steroid Biochemistry and Molecular Biology, Vol. 168, Issue. , p. 19.
    Patel, Seema Rauf, Abdur Khan, Haroon and Abu-Izneid, Tareq 2017. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. Biomedicine & Pharmacotherapy, Vol. 94, Issue. , p. 317.
    Gupta, Anil 2017. Exploring the Nutrition and Health Benefits of Functional Foods. p. 376.
    Paulos, Mark and Miner, Martin 2016. Male Sexual Dysfunction. p. 109.
    Mainasara, A.S. Isa, S.A. Dandare, A. Ladan, M.J. Saidu, Y. and Rabiu, S. 2016. Blood pressure profile and insulin resistance in salt-induced hypertensive rats treated with camel milk. Mediterranean Journal of Nutrition and Metabolism, Vol. 9, Issue. 1, p. 75.
    Gulati, Om P. 2015. Pycnogenol® in Metabolic Syndrome and Related Disorders. Phytotherapy Research, Vol. 29, Issue. 7, p. 949.
    Shamsuzzaman, Abu Szczesniak, Rhonda D. Fenchel, Matthew C. and Amin, Raouf S. 2015. Plasma renin levels and renin–blood pressure relationship in normal-weight and overweight children with obstructive sleep apnea and matched controls. Sleep Medicine, Vol. 16, Issue. 1, p. 101.
    Loh, Wei Mee Ling, Wei Chih Murugan, Dharmani D. Lau, Yeh Siang Achike, Francis I. Vanhoutte, Paul M. and Mustafa, Mohd Rais 2015. Des-aspartate angiotensin I (DAA-I) reduces endothelial dysfunction in the aorta of the spontaneously hypertensive rat through inhibition of angiotensin II-induced oxidative stress. Vascular Pharmacology, Vol. 71, Issue. , p. 151.
    Jeyabalan, Arun Hubel, Carl A. and Roberts, James M. 2015. Chesley's Hypertensive Disorders in Pregnancy. p. 133.
    Campioli, E Martinez-Arguelles, D B and Papadopoulos, V 2014. In utero exposure to the endocrine disruptor di-(2-ethylhexyl) phthalate promotes local adipose and systemic inflammation in adult male offspring. Nutrition & Diabetes, Vol. 4, Issue. 5, p. e115.
    Jung, Dong-Hyuk Kim, Jang-Young Kim, Jong-Koo Koh, Sang-Baek Park, Jong-Ku and Ahn, Song Vogue 2014. Relative contribution of obesity and serum adiponectin to the development of hypertension. Diabetes Research and Clinical Practice, Vol. 103, Issue. 1, p. 51.
    Wen, Chorng-Kai and Lee, Tzung-Yan 2014. Electroacupuncture Decreases the Leukocyte Infiltration to White Adipose Tissue and Attenuates Inflammatory Response in High Fat Diet-Induced Obesity Rats. Evidence-Based Complementary and Alternative Medicine, Vol. 2014, Issue. , p. 1.
    Khabour, Omar F. Wehaibi, Suha H. Al-Azzam, Sayer I. Alzoubi, Karem H. and El-Akawi, Zeyad J. 2013. Association of Adiponectin with Hypertension in Type 2 Diabetic Patients: the Gender Effect. Clinical and Experimental Hypertension, Vol. 35, Issue. 5, p. 361.
    Ali, Zarqa and Ulrik, Charlotte Suppli 2013. Obesity and asthma: A coincidence or a causal relationship? A systematic review. Respiratory Medicine, Vol. 107, Issue. 9, p. 1287.
    Nordstrand, Njord Hertel, Jens K. Hofsø, Dag Sandbu, Rune Saltvedt, Erling Røislien, Jo Os, Ingrid and Hjelmesæth, Jøran 2012. A controlled clinical trial of the effect of gastric bypass surgery and intensive lifestyle intervention on nocturnal hypertension and the circadian blood pressure rhythm in patients with morbid obesity. Surgery, Vol. 151, Issue. 5, p. 674.
    Islam, Mohammad Khan, Ismail Attia, John Hassan, Sheikh McEvoy, Mark D'Este, Catherine Azim, Syed Akhter, Ayesha Akter, Shahnaz Shahidullah, Sheikh and Milton, Abul 2012. Association between Hypertension and Chronic Arsenic Exposure in Drinking Water: A Cross-Sectional Study in Bangladesh. International Journal of Environmental Research and Public Health, Vol. 9, Issue. 12, p. 4522.
    Toque, Haroldo A. da Silva, Fábio H. Calixto, Marina C. Lintomen, Letícia Schenka, André A. Saad, Mario J. Zanesco, Angelina and Antunes, Edson 2011. High-fat diet associated with obesity induces impairment of mouse corpus cavernosum responses. BJU International, Vol. 107, Issue. 10, p. 1628.
    Hsueh, Willa A. and Wyne, Kathleen 2011. Renin-Angiotensin-Aldosterone System in Diabetes and Hypertension. The Journal of Clinical Hypertension, Vol. 13, Issue. 4, p. 224.
    Download full list
    ×
  • Access

Obesity, essential hypertension and renin–angiotensin system

  • Julian Segura (a1) and Luis M Ruilope (a1)
Abstract

Abdominal obesity is a risk factor for cardiovascular disease worldwide, and it is becoming a dramatic issue for national health systems. Overweight and obesity are highly associated with multiple comorbidities, elevated blood pressure values, dyslipidaemia, reduced insulin sensitivity and alterations of large and minor vessels.

Activation of the renin–angiotensin system (RAS) in adipose tissue may represent an important link between obesity and hypertension. Angiotensin II has been shown to play a role in adipocyte growth and differentiation. Adipocytes also secrete adiponectin, enhancing insulin sensitivity and preventing atherosclerosis. Blockade of the RAS with either an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker results in a substantial increase in adiponectin levels and improved insulin sensitivity. Obesity-related hypertension needs a comprehensive approach to treatment including both weight loss and pharmacological therapies. Antihypertensive drugs prescription should be based on guidelines recommendations for management of hypertension, taking into account the growing evidences about the relationship between some antihypertensive drugs and the development of new-onset diabetes.

This review discusses the role of RAS in the relationship between obesity, essential hypertension and insulin resistance.

    •
      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Obesity, essential hypertension and renin–angiotensin system
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Obesity, essential hypertension and renin–angiotensin system
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Obesity, essential hypertension and renin–angiotensin system
      Available formats
      ×
Copyright
COPYRIGHT: © The Authors 2007
Corresponding author
Corresponding author: Email juliansegura@mi.madritel.es
References
Hide All
1Freedman, DS, Khan, LK, Serdula, MK, Galuska, DA, Dietz, WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 2002; 288: 1758–1761.
2Thompson, D, Edelsberg, J, Colditz, GA, Bird, AP, Oster, G. Lifetime health and economic consequences of obesity. Archives of Internal Medicine 1999; 159: 2177–2183.
3Meigs, JB. Epidemiology of the insulin resistance syndrome. Current Diabetes Report 2003; 3: 73–79.
4Haffner, S, Taegtmeyer, H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541–1545.
5Sharma, AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension?0. Hypertension 2004; 44: 12–19.
6Hall, JE. The kidney, hypertension and obesity. Hypertension 2003; 41 (Part 2): 625–633.
7Hall, JE, Henegar, JR, Shek, EW, Brands, MW. Role of renin–angiotensin system in obesity hypertension. Circulation 1997; 96: I–33.
8Robles, RG, Villa, E, Santirso, R, Martinez, J, Ruilope, LM, Cuesta, C, et al. . Effects of captopril on sympathetic activity, lipid and carbohydrate metabolism in a model of obesity-induced hypertension in dogs. American Journal of Hypertension 1993; 6: 1009–1019.
9Reisen, E, Weir, M, Falkner, B, Hutchinson, HG, Anzalone, DA, Tuck, ML. Lisinoprin versus hydrochlorothiazide in obese hypertensive patients. Hypertension 1997; 30: 140–145.
10Engeli, S, Sharma, AM. Role of adipose tissue for cardiovascular-renal regulation in health and disease. Hormone and Metabolic Research 2000; 32: 485–499.
11Ailhaud, G, Fukamizu, A, Massiera, F, Negrel, R, Saint-Marc, P, Teboul, M. Angiotensinogen, angiotensin II and adipose tissue development. International Journal of Obesity Related Metabolic Disorder 2000; 24: S33–S35.
12Rotimi, C, Cooper, R, Ogunbiyi, O, Morrison, L, Ladipo, M, Tewksbury, D, et al. . Hypertension, serum angiotensinogen, and molecular variants of the angiotensinogen gene among Nigerians. Circulation 1997; 95: 2348–2350.
13Pratt, JH, Ambrosius, WT, Tewksbury, DA, Wagner, MA, Zhou, L, Hanna, MP. Serum angiotensinogen concentration in relation to gonadal hormones, body size, and genotype in growing young people. Hypertension 1998; 32: 875–879.
14Massiera, F, Bloch-Faure, M, Ceiler, D, Murakami, K, Fukamizu, A, Gasc, JM, et al. . Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB Journal 2001; 15: 2727–2729.
15Furuhashi, M, Ura, N, Takizawa, H, Yoshida, D, Moniwa, N, Murakami, H, et al. . Blockade of the renin–angiotensin system decreases adipocyte size with improvement in insulin sensitivity. Journal of Hypertension 2004; 22: 1977–1982.
16Yvan-Charvet, L, Even, P, Bloch-Faure, M, Guerre-Millo, M, Moustaid-Moussa, N, Ferre, P, et al. . Deletion of the angiotensin type 2 receptor (AT2R) reduces adipocyte cell size and protects from diet induced obesity and insulin resistance. Diabetes 2005; 54: 991–999.
17Ailhaud, G. Cross talk between adipocytes and their precursors: relationships with adipose tissue development and blood pressure. Annals of New York of Academic Science 1999; 892: 127–133.
18Cassis, LA, English, VL, Bharadwaj, K, Boustany, CM. Differential effects of local versus systemic angiotensin II in the regulation of leptin release from adipocytes. Endocrinology 2004; 145: 169–174.
19Arita, Y, Kihara, S, Ouchi, N, Takahashi, M, Maeda, K, Miyagawa, J, et al. . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical and Biophysical Research Communication 1999; 257: 79–83.
20Okamoto, Y, Kihara, S, Ouchi, N, Nishida, M, Arita, Y, Kumada, M, et al. . Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002; 106: 2767–2770.
21Furuhashi, M, Ura, N, Higashiura, K, Murakami, H, Tanaka, M, Moniwa, N, et al. . Blockade of the renin–angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76–81.
22Engeli, S, Böhnke, J, Gorzelniak, K, Janke, J, Schling, P, Bader, M, et al. . Weight loss and the renin–angiotensin–aldosterone system. Hypertension 2005; 45: 356–362.
23Rahmouni, K, Correia, MLG, Haynes, WG, Mark, AL. Obesity-associated hypertension. New insights into mechanisms. Hypertension 2005; 45: 9–14.
24Goodfriend, TL, Calhoun, DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43: 518–524.
25Ehrhart-Bornstein, M, Lamounier-Zepter, V, Schraven, A, Langenbach, J, Willenberg, HS, Barthel, A, et al. . Human adipocytes secrete mineralocorticoid-releasing factors. Proceedings of the National Academic Science USA 2003; 100: 14211–14216.
26Goodfriend, TL, Ball, DL, Egan, BM, Campbell, WB, Nithipatikom, K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358–363.
27de Paula, RB, da Silva, AA, Hall, JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004; 43: 41–47.
28Reaven, G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286–288.
29Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
30Cuspidi, C, Meani, S, Fusi, V, Severgnini, B, Valerio, C, Catini, E, et al. . Metabolic syndrome and target organ damage in untreated essential hypertensives. Journal of Hypertension 2004; 22: 1991–1998.
31Chen, J, Muntner, P, Hamm, LL, Jones, DW, Batuman, V, Fonseca, V, et al. . The metabolic syndrome and chronic kidney disease in US adults. Annals of Internal Medicine 2004; 140: 167–174.
32Safar, ME, Thomas, F, Blacher, J, Nzietchueng, R, Bureau, JM, Pannier, B, et al. . Metabolic syndrome and age-related progression of aortic stiffness. Journal of Amercian College of Cardiology 2006; 47: 72–75.
33Ford, ES, Giles, WH, Dietz, WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.
34Ford, ES, Giles, WH, Mokdad, AH. Increasing prevalence of the metabolic syndrome among US Adults. Diabetes Care 2004; 27: 2444–2449.
35Banegas, JR, Ruilope, LM. Epidemic of metabolic diseases. A warning call. Medicina Clinica (Barcelona) 2003; 120: 99–100.
36Segura, J, Campo, C, Roldan, C, Christiansen, H, Vigil, L, García-Robles, R, et al. . Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. Journal of American Society of Nephrology 2004; 15 (Suppl. 1): S37–S42.
37Bruno, G, Merletti, F, Biggeri, A, Bargero, G, Ferrero, S, Runzo, C, et al. . Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 2004; 27: 2689–2694.
38Alberti, KG, Zimmet, P, Shaw, J, for the IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.
39Grundy, SM, Hansen, B, JrSmith, SC, Cleeman, JI, Kahn, RA, American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551–556.
40Isomaa, B, Almgren, P, Tuomi, T, Forsen, B, Lahti, K, Nissen, M, et al. . Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683–689.
41Lakka, HM, Laaksonen, DE, Lakka, TA, Niskanen, LK, Kumpusalo, E, Tuomilehto, J, et al. . The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Journal of American Medical Association 2002; 288: 2709–2716.
42Yusuf, S, Hawken, S, Ounpuu, S, Dans, T, Avezum, A, Lanas, F, et al. ; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case–control study. Lancet 2004; 364: 937–952.
43Porier, P, Giles, TD, Bray, GA, Hong, Y, Stern, JS, Pi-Sunyer, FX, et al. . Obesity and cardiovascular disease. Pathophysiology, evaluation and effect of weight loss. Arteriosclerosis Thrombosis and Vascular Biology 2006; 26: 968–976.
44Schiel, R, Beltschikow, W, Kramer, G, Stein, G. Overweight, obesity and elevated blood pressure in children and adolescents. European Journal of Medical Research 2006; 11: 97–101.
45Srinivasan, SR, Myers, L, Berenson, GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects. The Bogalusa Heart Study. Hypertension 2006; 48: 33–39.
46Bacha, F, Saad, R, Gungor, N, Arslanian, SA. Are obesity-related metabolic risk factors modulated by the degree of insulin resistance in adolescents. Diabetes Care 2006; 29: 1599–1604.
47Banegas, JR, Segura, J, Ruilope, LM, Luque, M, García-Robles, R, Campo, C, et al. ; on behalf of the CLUE Study Group Investigators. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004; 43: 1338–1344.
48Chobanian, AV, Bakris, GL, Black, HR, Cushman, WC, Green, LA, JrIzzo, JL, et al. ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560–2571.
49Guidelines Committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension 2003; 21: 1011–1053.
50Sharma, AM, Pischon, T, Engeli, S, Scholze, J. Choice of drug treatment for obesity-related hypertension: where is the evidence? Journal of Hypertension 2001; 19: 667–674.
51Segura, J, Campo, C, Ruilope, LM, Rodicio, JL. Do we need to target ‘prediabetic’ hypertensive patients? Journal of Hypertension 2005; 23: 2119–2125.
52 Segura J, Ruilope LM. Antihypertensive therapy in patients with metabolic syndrome. Current Opinion in Nephrology and Hypertension 2006; 15: 493–497.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Public Health Nutrition
  • ISSN: 1368-9800
  • EISSN: 1475-2727
  • URL: /core/journals/public-health-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

Cancel
Confirm
×